Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Feb 15, 2008 (Vol. 28, No. 4)

[email protected]

  • Career info and links
  • Very limited content
Immunology at NIH, at first glance, would, logically, seem to be devoted mostly to the topic of immunology, but on closer examination, the site appears instead to be more about the people involved in the discipline than about immunology itself. The opening page provides four research snapshots, but clicking on them reveals little about immunology. For example, the heading titled Structural Biology brings up a pop-up window with a single image and a description referring to a single researcher. The same is true of the headings titled “Immune Cell Signaling”, “Autoimmunity”, and “Molecular Immunology,” except some also contain a single hyperlinked reference. Yawn. Is this the best the NIH could do? I think not. Other features of the site include a section related to careers at the NIH, interest groups, and links. At least the last items have a reasonable amount of content. I think this entire site needs to be rethought out before it’s ready for prime time.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »